Anzeige
Mehr »
Login
Donnerstag, 29.07.2021 Börsentäglich über 12.000 News von 667 internationalen Medien
Ein ganz wichtiger Meilenstein in Neufundland! Wer auf Gold setzt muß Leocor Gold kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PPX6 ISIN: US72941H4002 Ticker-Symbol: XMPA 
Frankfurt
29.07.21
08:04 Uhr
1,624 Euro
+0,110
+7,27 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
PLUS THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
PLUS THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,5861,64614:07
1,5821,64414:07

Aktuelle News zur PLUS THERAPEUTICS Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
PLUS THERAPEUTICS Aktie jetzt für 0€ handeln
DiPlus Therapeutics Inc.: Plus Strengthens Commercial RNL Supply Chain with Ten Year Exclusivity Agreement9
FrPlus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q2 2021 Results - Earnings Call Transcript2
22.07.EARNINGS SUMMARY: Details of Plus Therapeutics Inc. Q2 Earnings Report200WASHINGTON (dpa-AFX) - Below are the earnings highlights for Plus Therapeutics Inc. (PSTV):-Earnings: -$2.80 million in Q2 vs. -$1.84 million in the same period last year. -EPS: -$0.25 in...
► Artikel lesen
22.07.Plus Therapeutics Shares Jump As First Patient Treated In Latest Cohort Of Brain Tumor Trial1
22.07.SOS, ITRM and PSTV among premarket gainers1
22.07.Plus Therapeutics jumps 11% on treatment of first patient in latest cohort of ReSPECT-GBM trial1
15.07.Plus Therapeutics Inc.: Plus Therapeutics to Announce Second Quarter 2021 Financial Results and Host Conference Call on July 22, 20212
06.07.PLUS THERAPEUTICS, INC. - 10-Q/A, Quaterly Report3
16.06.Plus Therapeutics Gets DSMB Approval To Start Eighth Cohort For Glioblastoma Trial3
16.06.Plus Therapeutics Inc.: Plus Therapeutics Announces DSMB Approval to Proceed into Eighth Cohort in ReSPECT Glioblastoma Trial2
10.06.Plus Therapeutics Inc.: Plus Therapeutics Presents at the Sixth Biennial Pediatric Neuro-Oncology Research Conference1
09.06.Plus Therapeutics Inc.: Plus Therapeutics to Participate in BIO Digital Conference-
20.05.PLUS THERAPEUTICS, INC. - 8-K, Current Report2
04.05.Plus Therapeutics shares rise 5% on Rhenium NanoLiposome development contract4
04.05.Plus Therapeutics Inc.: Plus Therapeutics Announces Key RNL Development and cGMP Drug Manufacturing Collaboration Agreements5
23.04.Plus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q1 2021 Results - Earnings Call Transcript4
22.04.EARNINGS SUMMARY: Details of Plus Therapeutics Inc. Q1 Earnings Report482WASHINGTON (dpa-AFX) - Below are the earnings highlights for Plus Therapeutics Inc. (PSTV):-Earnings: -$2.72 million in Q1 vs. -$1.09 million in the same period last year. -EPS: -$0.33 in...
► Artikel lesen
22.04.Plus Therapeutics EPS beats by $0.035
22.04.Plus Therapeutics Inc.: Plus Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights5
08.04.Plus Therapeutics Inc.: Plus Therapeutics to Announce First Quarter 2021 Financial Results and Host Conference Call on April 22, 20214
Seite:  Weiter >>
39 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1